Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs
October 22, 2026
October 22, 2026
NEW YORK, Oct. 22 [Category: BizHospital] -- NYU Langone Health, an academic medical center affiliated with New York University, posted the following news release:
* * *
Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs
*
NYU Langone Health today announced the appointment of Vivek Subbiah, MD, as director of the Early Phase Drug Development Program and the Rare Cancer Program at NYU L . . .
* * *
Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs
*
NYU Langone Health today announced the appointment of Vivek Subbiah, MD, as director of the Early Phase Drug Development Program and the Rare Cancer Program at NYU L . . .